Literature DB >> 8838433

Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life.

F H Leenen1, A Fourney, G Notman, J Tanner.   

Abstract

1. Calcium antagonists with long vs short elimination half-life may show marked differences in their antihypertensive effect during short interruptions of therapy by missed doses. 2. In the present study we evaluated the blood pressure lowering effect of amlodipine vs diltiazem both on active maintenance treatment and after active treatment was interrupted for 2 days by placebo using a double-blind randomized design. After a single blind placebo run-in period, hypertensive patients were randomized to amlodipine 5 mg once daily or diltiazem 90 mg twice daily. After 4-6 weeks, doses were increased to 10 mg once daily or 180 mg twice daily, if necessary for control of diastolic blood pressure. During week 9 or 10 on active treatment blisterpacks contained 2 days of placebo. Twenty-four hour blood pressure monitoring was performed at the end of run-in period and during week 9 and 10 on active vs interrupted therapy. 3. Active therapy by amlodipine (n = 20) lowered day systolic blood pressure by 17 +/- 2 mmHg and diastolic blood pressure by 12 +/- 2 mmHg and did not change heart rate. In second day of interrupted therapy most of these responses were still present. Diltiazem (n = 14) lowered day systolic blood pressure by 13 +/- 2 mmHg, diastolic blood pressure by 11 +/- 2 mmHg and heart rate by 10 +/- 2 beats min-1. Most of these responses had disappeared during the second day of interrupted therapy. 4. We conclude that amlodipine and diltiazem are fairly similar in lowering blood pressure from an efficacy point of view. However, during short periods of noncompliance blood pressure control will persist markedly better with the agent with a long vs the one with a short elimination half-life.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838433     DOI: 10.1111/j.1365-2125.1996.tb00164.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Importance of various methods of blood pressure measurement in clinical trials.

Authors:  P Palatini
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

Review 2.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study.

Authors:  Donald Redelmeier; Damon Scales; Alexander Kopp
Journal:  BMJ       Date:  2005-10-06

4.  Persistence of anti-hypertensive effect after missed dose of perindopril.

Authors:  K W Tan; F H Leenen
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

5.  The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients.

Authors:  Peter W de Leeuw; Robert Fagard; Abraham A Kroon
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

Review 6.  Role of a third generation calcium antagonist in the management of hypertension.

Authors:  M Epstein
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  Patterns of nonadherence to antihypertensive therapy in primary care.

Authors:  Larissa Grigoryan; Valory N Pavlik; David J Hyman
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-26       Impact factor: 3.738

8.  Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an asian multinational population.

Authors:  S H Taylor; M F Chen; S J Lee; B Koanantakul; J R Zhu; T Santoso; R G Sy; Y T Tai
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devices.

Authors:  Dyfrig Hughes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Authors:  S Oparil; D Williams; S G Chrysant; T C Marbury; J Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Sep-Oct       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.